Friday, April 24, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 24, 2026
FDA citizen petition calls on agency to tighten up CRL disclosure practices
background ▾
- •The FDA's new CRL disclosure practice is now formally contested through the citizen petition process, signaling industry concern about unintended competitive exposure.
- •Uncertainty remains regarding the FDA's rationale for expanded CRL transparency and whether the agency will modify, clarify, or defend its current disclosure approach.
Policy•Fierce Pharma•Apr 24, 2026
Patients less confident than ever about health choices: survey
background ▾
- •Patient confidence in health decision-making has significantly declined year-over-year according to Edelman survey data
Policy•Fierce Pharma•Apr 24, 2026
Regeneron unveils latest 'most favored nation' drug pricing deal with White House
background ▾
- •All 17 companies targeted by the Trump administration have now agreed to MFN pricing deals, signaling broad industry acceptance of this new pricing framework
- •The MFN strategy represents a material policy shift that could fundamentally alter U.S. pharmaceutical pricing dynamics and establish precedent for future administrations
- •Monitor implementation timelines, which drugs are actually covered under these agreements, actual price reductions achieved, and potential legal/regulatory challenges to the MFN authority
Regeneron
→ Read original articlePolicy•Fierce Pharma•Apr 24, 2026
More than 60% of Americans using AI tools for medical information: survey
background ▾
- •Majority adoption of AI for medical information seeking (>60%) indicates a significant shift in patient information behavior that pharma and regulators must address
- •One-third distrust AI medical tools despite using them, suggesting need for transparency standards and regulatory guidance on AI-generated medical content
Policy•Endpoints News•Apr 24, 2026
Daiichi Sankyo postpones annual results, stock dips
background ▾
- •Daiichi Sankyo postponed annual results reporting without disclosed reason or revised timeline
Daiichi Sankyo
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 23, 2026
Kurma closes €215M Europe-focused fund to spread across 20 biotechs
background ▾
- •Kurma closed €215M fund at 14% below target amid difficult biotech fundraising climate, signaling investor caution despite European VC activity
- •Fund structure emphasizes integrated ecosystem model bridging academic discovery through Argobio Studio to mature-stage companies, with track record of successful exits (Emergence Therapeutics acquired by Eli Lilly for $406.5M R&D expense)
- •Portfolio includes high-profile bets on obesity (Alveus Series A $159.8M) and ADC space (Adcytherix €105M Series A), positioning fund to capitalize on validated therapeutic areas
Kurma PartnersAlveus TherapeuticsAdcytherix
→ Read original articleMarket Access•Fierce Biotech•Apr 23, 2026
From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree
background ▾
- •Roche deliberately avoiding near-term acquisitions to preserve balance sheet strength and avoid debt in elevated interest rate environment, contrasting with competitors facing patent cliffs
- •CEO emphasized robust pipeline depth (19 potential launches by 2030) reduces M&A urgency and supports organic growth strategy, with near-term catalysts including fenebrutinib filing and giredestrant FDA submission
- •Monitor Roche's execution on obesity portfolio (enicepatide, petrelintide) and MS therapy fenebrutinib as key tests of organic pipeline strategy; reassess if interest rates decline or competitive pressures mount
RocheEli LillyBiogenSyfovreEmpavelienicepatide
→ Read original articleMarket Access•STAT News•Apr 23, 2026
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
background ▾
- •Eli Lilly's $3.25 billion acquisition of Kelonia demonstrates investor and pharma confidence in CAR-T despite the biotech's severe financial challenges, suggesting strong underlying assets or technology justifying the premium valuation
- •Pharma companies are adopting unconventional go-to-market tactics via low-cost telehealth platforms to drive prescriptions, potentially indicating market saturation concerns or difficulty reaching patients through traditional channels
- •Watch for regulatory scrutiny of telehealth-pharma partnerships and whether this distribution model proves sustainable as payers and regulators evaluate patient outcomes and appropriate prescribing practices
Eli LillyKelonia TherapeuticsPrescribery
→ Read original articleMarket Access•Fierce Pharma•Apr 24, 2026
With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivity
background ▾
- •Dupixent represents 40% of Sanofi's Q1 sales, making patent cliff mitigation in 2031 commercially critical
- •Sanofi is pursuing multiple exclusivity extension strategies beyond the compound patent expiration
- •Monitor for pediatric indication approvals, new formulation patents, or additional indication filings that could extend market exclusivity
SanofiDupixent
→ Read original articleMarket Access•Fierce Pharma•Apr 24, 2026
Roche Q1 earnings suffer blood bath, but currency headwinds aren’t the only culprit
background ▾
- •Roche's Q1 pharma division sales missed consensus by a material margin, with currency headwinds masking additional deterioration in underlying demand
- •Key drugs underperformed expectations, indicating competitive or reimbursement pressures that FX alone cannot explain
- •Investors and analysts will scrutinize whether this reflects broader portfolio weakness or transient market access obstacles
Roche
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 23, 2026
Despite data concerns, Roche’s oral SERD can still be largest product in company history: exec
background ▾
- •Giredestrant's adjuvant early-stage breast cancer opportunity (~70% of total potential) vastly exceeds the failed first-line metastatic setting (~10%), with the adjuvant market representing $20-30B annually and three times more treated patients than first-line metastatic disease
- •Positive lidERA phase 3 readout showed 30% reduction in invasive disease recurrence/death risk, but lacked direct comparison to CDK4/6 inhibitors (standard of care) and has not demonstrated overall survival benefit to date
- •Watch for: adjuvant regulatory decisions and label positioning relative to CDK4/6 inhibitors; real-world uptake patterns among medium and high-risk patients; AstraZeneca's Cambria-1 and -2 results (expected 2027) in competing oral SERD space; additional giredestrant combination therapy data
RocheNovartisEli LillygiredestrantKisqaliVerzenio
→ Read original articleClinical Trials•Fierce Pharma•Apr 24, 2026
With trial win, Novo Nordisk eyes adolescent diabetes approval for oral semaglutide
background ▾
- •Positive adolescent type 2 diabetes trial results create a differentiated market opportunity, as few GLP-1 competitors have demonstrated efficacy in this younger population
- •Oral semaglutide approval in adolescents would expand the total addressable market and establish Novo Nordisk's GLP-1 franchise across obesity and diabetes in both adult and pediatric segments
- •Watch for regulatory submissions (likely FDA/EMA) in coming quarters and competitive moves by Eli Lilly and other GLP-1 developers to pursue similar pediatric indications
Novo NordisksemaglutideWegovy
→ Read original articleClinical Trials•Fierce Biotech•Apr 23, 2026
Pfizer cans work on next-gen conjugate in cancer patients
background ▾
- •Pfizer discontinued PF-08046037 development entirely after minimal patient enrollment (8 patients) in Phase 1, signaling weak commercial interest or strategic portfolio deprioritization rather than safety signals
- •The decision reflects challenging early adoption of ISACs as a therapeutic modality despite theoretical immunological appeal, with competitor Bolt Therapeutics also under financial strain in this space
PfizerBolt TherapeuticsPF-08046037sasanlimabBDC-4182
→ Read original articleClinical Trials•Endpoints News•Apr 23, 2026
Substance use disorder biotech Tempero to close after earlier 'serious' safety event
background ▾
- •Tempero Bio is shutting down after encountering a 'serious' safety event in its development program, indicating potential clinical trial complications or adverse events that undermined investor/regulatory confidence.
- •The closure removes a competitor from the substance use disorder treatment market, which has been an active area of drug development and commercial opportunity.
- •Details on the specific safety event and which candidate(s) were affected remain unclear and warrant monitoring for regulatory disclosures or clinical trial database updates.
Tempero Bio
→ Read original articleClinical Trials•Endpoints News•Apr 23, 2026
Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
background ▾
- •Rybelsus demonstrated efficacy in pediatric type 2 diabetes (ages 10–17), potentially opening a new patient population for Novo's oral GLP-1 franchise
- •Pediatric GLP-1 approvals could reshape obesity and diabetes treatment paradigms in children and influence payer coverage discussions
- •Watch for full trial data disclosure, EMA/FDA pediatric labeling submissions, and competitive pediatric GLP-1 developments from Eli Lilly and others
Novo NordiskAltimmuneMerckRybelsus
→ Read original article